News

Developed by Biosenta Inc. and enhanced by University of Calgary researchers, "Tri-Filler" is a breakthrough antimicrobial additive that continuously reduces surface bacteria. Led by Dr. Maen Husein, researchers formulated Tri-Filler by entrapping calcium hydroxide in a calcium carbonate shell, which releases its antibacterial component over time. It is over 200 times more effective than calcium hydroxide alone and can be added to paint and concrete to create self-cleaning en

Researchers at the University of Calgary have developed a new antimicrobial agent that offers long-lasting protection for high-touch surfaces.

Find out how Tri-Filler nanostructures outperform a common antibacterial compound by 230 times, paving the way for long-term self-sanitizing surfaces in high-traffic areas.

Biosenta Inc. highlighted new University of Calgary research showing its Tri-Filler™ antimicrobial nanotechnology achieved a 200-fold improvement in antibacterial performance over common compounds. Testing confirms the core-shell technology maintains its structural integrity and antibacterial properties for over a year under elevated temperature and humidity. Biosenta is now advancing Tri-Filler toward commercialization for use in high-contact building materials like paints a

Explore Biosenta's groundbreaking field-test of antimicrobial nanoparticles in Alberta's multi-unit build. Discover how Biosenta's innovation enhances home safety.

Biosenta Inc. announced that Gary LeRoux, past President and CEO of the Canadian Coatings Association (CCA), has joined the company’s advisory board. Mr. LeRoux brings more than 30 years of leadership experience. “Gary’s unmatched experience in coatings, regulatory policy, and industry partnerships is a tremendous asset as we advance the commercialization of Tri-­Filler®,” said Am Gill, President and CEO of Biosenta. “His perspective will help us accelerate adoption across ke

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

A University of Calgary research team, partnered with Biosenta Inc., has developed a method to transform limestone into a long-lasting antimicrobial nanoparticle. This new "shell and core" technology has a durable active ingredient, calcium hydroxide, and has been proven effective against various harmful pathogens. Potential applications include enhancing concrete, paint for healthcare settings, and coatings for food packaging and high-touch surfaces.

Kris Hans shares how Biosenta is tackling the antimicrobial health crisis at the source, and why this work matters now more than ever.

Biosenta Inc. Achieves Major Breakthroughs in Bench Scale Production and Innovative Input Viability.

Biosenta announces significant advancements at its state-of-the-art bench scale production facility.

Biosenta has been making the innovative strides in the realm of antimicrobial biotechnology.

Biosenta Inc. announces licensing agreement

Biosenta announces technological and operational advancements with successful construction and operation of a bench scale production plant.

Biosenta announces a pivotal discovery revealed that Tri-Filler™ effectively sterilizes a wide range of microorganisms.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta Inc. announces further advances in research and development of Tri-Filler™

UoC professor taking about a solution fighting a drug-resistant fungus that has become a big issue for hospitals in the U.S. and Canada.